Bristol-Myers Squibb Company

BMY

$68.09

+0.64%

2026-09-03 16:00:03 EDT+$0.43

Healthcare

Drug Manufacturers - General

NYSE

Active Trading

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its ...

Price Action of BMY

$68.09

+0.64%+$0.43

High—

Low—

52W High-0.8%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical entity headquartered in New York, with operations spanning research, development, licensing, production, and commercialization of medicines. Founded in 1887 as Clinton Pharmaceuticals by William McLaren Bristol and John Ripley Myers, the company has evolved through mergers, including the 1989 merger with Squibb, ...Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical entity headquartered in New York, with operations spanning research, development, licensing, production, and commercialization of medicines. Founded in 1887 as Clinton Pharmaceuticals by William McLaren Bristol and John Ripley Myers, the company has evolved through mergers, including the 1989 merger with Squibb, to become a leader in oncology, hematology, cardiovascular, immunology, and neuroscience. Key products include Revlimid for multiple myeloma, Eliquis an anticoagulant, Opdivo for various cancers, and breakthroughs like Breyanzi, a CAR-T therapy. Financially, BMS reported a market cap of ~$132 billion, with a price-to-earnings ratio of 14.1, a gross profit margin of 70.2%, and a dividend yield of ~3.9%. The company employs ~32,500 people, with R&D spending at 21.8% of revenue, indicating strong investment in innovation. Led by CEO Christopher Boerner, BMS distributes through a diverse network including wholesalers, hospitals, and government entities. With a legacy of over 135 years, BMS continues to focus on transforming patient lives through science, addressing unmet medical needs globally, and maintaining a robust pipeline of novel therapies.ExpandCollapse

Founded

1887

Employees

32500

CEO

Christopher Boerner

Full Name

Bristol-Myers Squibb Company

Sector

Healthcare

Industry

Drug Manufacturers - General

ROE

46.75%

Market Cap

$139.09B

Current Ratio

1.53

WACC

5.17%

ROIC

18.69%

Contact Information

https://www.bms.com

609 252 4621

Route 206 & Province Line Road, Princeton, NJ 08543

Key Metrics of BMY

Snapshot

Latest / TTM · 6 periods

Market Cap

$139.09B

ROCE

20.2%

EV / EBITDA

10.39x

-0.4% YoY

FCF Yield

8.2%

-3.4% YoY

Cash Conversion Cycle

43.0d

Current Ratio

1.53

Quick take

TTM —

Positive CCC

Financial Highlights of BMY

Profitability trend

Latest / TTM · 6 periods

Gross Margin

70.2%

Net Margin

18.9%

P/E Ratio

14.97x

n/a

Debt / Equity

1.93

n/a

Current Ratio

1.53

Dividend Yield

3.7%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of BMY

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $1.72 · Revenue $12.59B · 14 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $1.59 · Revenue $12.64B · 13 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $6.93 · Revenue $49.55B · 16 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $1.45 · Revenue $11.16B · 5 analysts

Recent history

Aug 3, 2026
Dividend payment
$2.51 per share
Jul 30, 2026
Q2 FY2026 · Results reported
EPS $1.62 · Revenue $12.97B
View filing
Jul 2, 2026
Ex-dividend date
$2.51 per share
Apr 30, 2026
Q1 FY2026 · Results reported
EPS $1.31 · Revenue $11.49B
View filing
Feb 11, 2026
FY2025 · Annual results
EPS $3.45 · Revenue $48.20B
View filing
Oct 30, 2025
Q3 FY2025 · Results reported
EPS $1.08 · Revenue $12.22B
View filing

Financial Statements of BMY

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$48.2B	-0.2%	+12.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$7.1B	+178.8%	+23.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+71.1%	+25.2%	+1.5%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+28.5%	+42.4%	+7.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+14.6%	+179.0%	+9.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$12.8B	-7.9%	+307.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+26.7%	-7.7%	+261.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	255.2%	-18.6%	-16.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.26x	+0.2%	+7.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$90.0B	-2.8%	+1.3%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	3.45 vs 6.11	-43.6%	1.62 vs 1.72	-6.0%
Revenue Surprise	$48.2B vs $48.0B	+0.4%	$13.0B vs $12.6B	+3.0%

Insider Transactions of BMY

Acquisitions (A)

Since Jun 30, 2026

Disposals (D)

Since Jun 30, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 25, 2026	Holzer Phil M	officer: SVP and Controller	Common Stock, $0.10 par value	D	500	$67.50
Aug 1, 2026	Massacesi Cristian	officer: EVP,Chief Med Offr,Head of Dev	Restricted Stock Units	D	51,172	—
Aug 1, 2026	Massacesi Cristian	officer: EVP,Chief Med Offr,Head of Dev	Common Stock, $0.10 par value	A	51,172	—
Aug 1, 2026	Massacesi Cristian	officer: EVP,Chief Med Offr,Head of Dev	Common Stock, $0.10 par value	D	26,175	$65.31
Aug 1, 2026	Gallman Cari	officer: EVP, General Counsel	Common Stock, $0.10 par value	A	1,061	—

Earnings Call Transcript of BMY

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Welcome to the Bristol-Myers Squibb Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Chuck Triano, Senior Vice President and Head of Investor Relations. Please go ahead. Charles Triano: Thank you, and good morning, everyone. We appreciate you joining our second quarter 2026 earnings call. With me this morning with prepared remarks are Chris Boerner, our Board Chair and Chief Executive Officer; and David Elkins, our Chief Financial Officer. Also participating in today's call is Adam Lenkowsky, our Chief Commercialization Officer; and Cristian Massacesi, our Chief Medical Officer and Head of Global Drug Development. Earlier this morning, we posted our quarterly slide presentation to bms.com that you can use to follow along with Chris and David's remarks. Before we get started, I'll remind everybody that during this call, we will make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date, and we specifically disclaim any obligation to update forward-looking statements even if our estimates change. We'll also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measures are available at bms.com. Finally, unless otherwise stated, all comparisons are made from the same period in 2025, and sales growth rates will be discussed on an underlying basis, which excludes the impact of foreign exchange. All references to our P&L are on a non-GAAP basis. And with that, I'll hand it over to Chris. Christopher Boerner: Thanks, Chuck. Good morning, everyone, and thank you for joining our Q2 2026 earnings call. We delivered another excellent quarter, driven by disciplined execution across the business. Our progress towards transitioning the portfolio to fuel durable long-term growth is reflected in our growth portfolio's strong Q2 performance. At the same time, we're delivering strong performance from our existing business. We're also advancing a broad and differentiated pipeline while maintaining financial flexibility to invest in the highest value opportunities for patients and shareholders. Together, these efforts continue to strengthen the foundation we're building and increase our confidence in our ability to grow the company as we exit the decade. Let me walk you through some of the highlights of our performance, beginning with our Q2 results on Slide 4. Our growth portfolio continued its strong performance with sales …

Leadership Team of BMY

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Christopher S. Boerner	Chief Executive Officer & Chairman	USD 5,818,520	—	1971	Active
David V. Elkins	Executive Vice President & Chief Financial Officer	USD 3,196,077	Male	1968	Active
Adam Lenkowsky	Executive Vice President & Chief Commercialization Officer	USD 3,176,492	Male	1972	Active
Greg Meyers	Executive Vice President and Chief Digital & Technology Officer	USD 2,972,005	Male	1973	Active
Karin Shanahan	Executive Vice President, Chief Supply Chain & Operations Officer	USD 2,420,673	Female	1965	Active
Cristian Massacesi	Executive Vice President, Chief Medical Officer & Head of Development	USD 2,218,956	Male	1969	Active
Charles E. Triano	SVP & Head of Investor Relations	—	Male	—	Active
Joseph J. Eiden Jr.	Head of Medical Affairs	—	—	1949	Active
Cari Gallman	Executive Vice President, General Counsel & Chief Policy Officer	—	Female	1980	Active
Ahn Amanda Poole	Executive Vice President & Chief People Officer	—	Female	1975	Active

Recent News of BMY

Zacks Investment Research8/14/2026Neutral

Can BMY's First CELMoD Approval Support Its Growth Strategy?

Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.

The Motley Fool8/14/2026Neutral

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio. Bristol-Myers Squibb maintains high net margins while trading at a significant valuation discount to its peer.

Fool - Investing News8/14/2026Neutral

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

The Motley Fool8/13/2026Neutral

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion.

Business Wire8/13/2026Neutral

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS.

Historical Employee Count of BMY

Current

32,500

Change

-4.69%

Minimum

32,200

Maximum

34,300

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	32,500	10-K	Feb 11, 2026	View
Dec 31, 2024	34,100	10-K	Feb 12, 2025	View
Dec 31, 2023	34,100	10-K	Feb 13, 2024	View
Dec 31, 2022	34,300	10-K	Feb 14, 2023	View
Dec 31, 2021	32,200	10-K	Feb 9, 2022	View

Related stocksDrug Manufacturers - General

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Bristol-Myers Squibb Company